Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 16972300 | COMBINATIONS OF BETA-LACTAM COMPOUNDS AND PROBENECID AND USES THEREOF | December 2020 | September 2022 | Allow | 21 | 4 | 1 | Yes | No |
| 17097465 | TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINS | November 2020 | February 2024 | Abandon | 39 | 3 | 0 | No | No |
| 17084506 | Grip Enhancing Compositions, and Methods and Uses Thereof | October 2020 | November 2022 | Abandon | 25 | 1 | 0 | No | No |
| 17051767 | MICROSPHERE FOR EMBOLIZATION, PREPARATION METHOD THEREOF, AND METHOD FOR EMBOLIZING TUMOR USING THE SAME | October 2020 | September 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17049476 | ORALLY DISINTEGRATING TABLETS COMPRISING GLYCOPYRROLATE AND METHODS FOR INCREASING BIOAVAILABILITY | October 2020 | June 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17069303 | MEDICINAL DELIVERY SYSTEM AND RELATED METHODS | October 2020 | June 2023 | Abandon | 32 | 2 | 0 | No | No |
| 16963846 | GEL PRODUCT INSTANT-DISSOLVING BLOCK AND PREPARATION METHOD THEREOF | July 2020 | September 2022 | Allow | 25 | 4 | 1 | Yes | No |
| 16954329 | COMPOSITION COMPRISING GLUCOSYLATED TERPENE GLYCOSIDES, TERPENE GLYCOSIDES AND CYCLODEXTRINE | June 2020 | April 2024 | Abandon | 46 | 3 | 0 | No | Yes |
| 16839703 | ORGANIC COMPOUNDS | April 2020 | November 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16822320 | Masking Bitter Flavors | March 2020 | December 2022 | Abandon | 33 | 1 | 0 | Yes | No |
| 16803982 | BIOCIDAL SURFACE | February 2020 | July 2021 | Abandon | 17 | 1 | 0 | Yes | No |
| 16780365 | MARKERS FOR PHARMACEUTICALS | February 2020 | September 2022 | Abandon | 32 | 2 | 0 | No | Yes |
| 16629532 | FIBROUS POLYMER MATERIAL COMPRISING FIBROIN AND POLYMER SCAFFOLDS COMPRISING THEREOF | January 2020 | April 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16720892 | TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION | December 2019 | February 2023 | Abandon | 38 | 1 | 0 | No | No |
| 16687972 | TABLET AND METHOD FOR MANUFACTURING THE SAME | November 2019 | October 2023 | Abandon | 47 | 2 | 1 | Yes | No |
| 16688924 | Oral Medicine Delivery Capsule | November 2019 | August 2023 | Abandon | 45 | 5 | 0 | Yes | No |
| 16683663 | Oral Care Compositions Comprising Charcoal | November 2019 | July 2023 | Abandon | 44 | 2 | 0 | No | No |
| 16612653 | COMPOSITION FOR DISINTEGRATING TABLETS CONTAINING MICROFIBROUS CELLULOSE AND ACTIVE INGREDIENT | November 2019 | September 2023 | Abandon | 46 | 2 | 0 | Yes | No |
| 16656674 | COMPOSITION COMPRISING CHARCOAL AND AN EXTRACT OR SUBSTANCE OF ASTROCARYUM MURUMURU | October 2019 | May 2023 | Abandon | 43 | 2 | 0 | Yes | No |
| 16599827 | ORAL CARE FORMULATION SYSTEM PROVIDING AMORPHOUS CALCIUM PHOSPHATE | October 2019 | November 2022 | Abandon | 37 | 2 | 0 | No | No |
| 16603969 | DISPENSING CAP CONTAINING A SOLUBILISATE OF A PHARMACEUTICALLY ACTIVE AGENT OR DIETARY SUPPLEMENT | October 2019 | June 2023 | Abandon | 44 | 4 | 1 | No | No |
| 16570184 | Oral Therapeutic Compound Delivery System | September 2019 | March 2023 | Abandon | 42 | 3 | 0 | Yes | Yes |
| 16566696 | Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs Thereof | September 2019 | December 2023 | Abandon | 51 | 6 | 0 | Yes | No |
| 16489786 | MULTI-DOMAIN VESICLE COMPRISING IMMUNOSUPPRESSIVE FACTOR CONTROL MATERIAL, PRODUCTION METHOD THEREFOR AND IMMUNOMODULATORY COMPOSITION COMPRISING SAME | August 2019 | October 2022 | Abandon | 38 | 3 | 1 | No | No |
| 16489781 | MULTI-DOMAIN VESICLE COMPRISING IMMUNOACTIVE MATERIAL, PRODUCTION METHOD THEREFOR AND IMMUNOMODULATORY COMPOSITION COMPRISING SAME | August 2019 | October 2022 | Abandon | 38 | 3 | 1 | No | No |
| 16553056 | PHARMACEUTICAL CARRIER IN THE PREPARATION OF AN ANTI-DIABETIC PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENT | August 2019 | January 2023 | Allow | 41 | 4 | 1 | Yes | No |
| 16524952 | REDUCED DOSE METAXALONE FORMULATIONS | July 2019 | March 2024 | Abandon | 56 | 8 | 0 | Yes | Yes |
| 16474882 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | June 2019 | September 2023 | Allow | 50 | 6 | 0 | Yes | No |
| 16474028 | ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS | June 2019 | September 2023 | Abandon | 51 | 4 | 1 | No | Yes |
| 16471519 | MAGNESIUM/LITHIUM PREPARATIONS FOR NEUROPROTECTION AND NEUROTROPHIC BENEFITS | June 2019 | September 2021 | Allow | 27 | 2 | 1 | Yes | No |
| 16444360 | METHODS AND COMPOSITIONS FOR MAKING AND USING NANOTHERAPEUTIC DRUG DELIVERY VEHICLES | June 2019 | September 2023 | Abandon | 51 | 4 | 1 | Yes | No |
| 16440907 | MULTIPARTICULATES OF SPRAY-COATED DRUG AND POLYMER ON A MELTABLE CORE | June 2019 | May 2021 | Allow | 23 | 3 | 0 | No | Yes |
| 16469593 | A CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEIN | June 2019 | June 2023 | Abandon | 48 | 4 | 1 | Yes | No |
| 16468862 | HAIR COMPOSITION COMPRISING A GUANIDINE SALT, AN ALKANOLAMINE, AMMONIUM HYDROXIDE AND A POLYOL | June 2019 | August 2023 | Abandon | 50 | 3 | 1 | Yes | No |
| 16398210 | ANAEROBIC ANTIOXIDANT COMPOSITION | April 2019 | January 2024 | Abandon | 57 | 5 | 0 | Yes | No |
| 16341670 | APPETITE CONTROL DEVICE | April 2019 | January 2023 | Abandon | 45 | 1 | 0 | No | No |
| 16338152 | A NEW DRUG DELIVERY SYSTEM FOR TREATMENT OF DISEASE | March 2019 | February 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16274357 | ORGANIC COMPOUNDS | February 2019 | May 2020 | Abandon | 15 | 1 | 0 | No | No |
| 16261444 | LIMITED RELEASE LINGUAL THIOCTIC ACID DELIVERY SYSTEMS | January 2019 | July 2022 | Allow | 42 | 6 | 0 | Yes | No |
| 16247605 | METHOD OF PREPARING PHARMACEUTICAL MICROSPHERE | January 2019 | November 2020 | Abandon | 23 | 1 | 0 | No | No |
| 16240642 | INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICE | January 2019 | December 2021 | Abandon | 36 | 2 | 1 | No | No |
| 16239222 | Alcohol-Resistant Formulations | January 2019 | January 2020 | Abandon | 13 | 1 | 0 | No | No |
| 16312692 | PHARMACEUTICAL PREPARATION FOR DELIVERY OF PEPTIDES AND PROTEINS | December 2018 | December 2020 | Abandon | 24 | 1 | 0 | Yes | No |
| 16220619 | ORALLY DISINTEGRATING TABLET HAVING INNER CORE | December 2018 | October 2020 | Abandon | 22 | 2 | 0 | Yes | No |
| 16216552 | WOOD PRESERVATIVE AND METHOD FOR PRODUCING SAME | December 2018 | June 2022 | Abandon | 42 | 5 | 0 | Yes | No |
| 16169952 | Grip Enhancing Compositions, and Methods and Uses Thereof | October 2018 | December 2020 | Abandon | 26 | 2 | 0 | No | No |
| 16084542 | TABLET | September 2018 | February 2023 | Abandon | 53 | 5 | 0 | Yes | No |
| 16084173 | FORMULATIONS FOR TREATING CONSTIPATION | September 2018 | December 2023 | Abandon | 60 | 0 | 1 | No | No |
| 16102711 | LIMITED RELEASE LINGUAL THIOCTIC ACID DELIVERY SYSTEMS | August 2018 | July 2021 | Abandon | 35 | 2 | 1 | No | No |
| 16038450 | SURFACE TREATED LIPID SUPPORTED MULTILAYERS | July 2018 | November 2022 | Abandon | 52 | 5 | 1 | Yes | No |
| 16067458 | Enteric coated oral pharmaceutical preparation comprising dimethyl fumarate | June 2018 | January 2023 | Abandon | 55 | 4 | 0 | Yes | No |
| 16005330 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | June 2018 | April 2022 | Abandon | 46 | 3 | 1 | No | No |
| 15992494 | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | May 2018 | August 2020 | Abandon | 26 | 0 | 1 | No | No |
| 15975577 | INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITH | May 2018 | August 2021 | Allow | 40 | 4 | 0 | Yes | No |
| 15770825 | PYRIMIDINE COMPOSITIONS, ULTRA-PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS | April 2018 | January 2021 | Abandon | 33 | 2 | 0 | No | No |
| 15955397 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | April 2018 | April 2021 | Abandon | 36 | 2 | 0 | Yes | Yes |
| 15941419 | ANTIMICROBIALS AND METHODS OF USE THEREOF FOR WOUND HEALING | March 2018 | August 2019 | Abandon | 16 | 3 | 0 | No | No |
| 15934595 | ORAL FORMULATIONS OF DEFERASIROX | March 2018 | May 2023 | Abandon | 60 | 2 | 0 | Yes | Yes |
| 15927703 | FULLERENE AND ITS USE TO MAINTAIN GOOD HEALTH AND TO PROLONG THE EXPECTED LIFESPAN OF MAMMALS | March 2018 | June 2022 | Allow | 51 | 4 | 1 | Yes | No |
| 15758953 | ARGININE-CONTAINING RESTORATIVE DENTAL MATERIALS AND METHODS OF PREVENTING AND CONTROLLING CARIES ASSOCIATED WITH DENTAL WORK | March 2018 | November 2020 | Abandon | 33 | 1 | 1 | No | No |
| 15914244 | MICRONEEDLE ARRAY | March 2018 | March 2022 | Abandon | 49 | 4 | 0 | Yes | No |
| 15913279 | TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINS | March 2018 | January 2021 | Abandon | 34 | 2 | 0 | No | No |
| 15912640 | GAMMA-HYDROXYBUTYRIC ACID GRANULES | March 2018 | March 2022 | Abandon | 49 | 3 | 1 | Yes | No |
| 15752951 | COMPOSITION FOR SKIN WHITENING COMPRISING BETA-MANGOSTIN AS EFFECTIVE INGREDIENT | February 2018 | December 2023 | Allow | 60 | 4 | 1 | Yes | Yes |
| 15879806 | RAPID DISSOLVE TABLET COMPOSITIONS FOR VAGINAL ADMINISTRATION | January 2018 | January 2020 | Abandon | 24 | 1 | 0 | No | No |
| 15736792 | MICRO-NANO MEDICAL ADSORBENT RESIN POWDER MATERIAL | December 2017 | November 2020 | Abandon | 36 | 1 | 1 | No | No |
| 15834537 | Oral Care Compositions | December 2017 | June 2023 | Abandon | 60 | 5 | 1 | No | No |
| 15834160 | Oral Care Compositions | December 2017 | June 2023 | Abandon | 60 | 5 | 1 | No | No |
| 15577362 | COSMETICS | November 2017 | August 2021 | Abandon | 45 | 3 | 0 | No | No |
| 15822762 | PROCESS FOR MAKING A COATED DOSAGE FORM | November 2017 | November 2023 | Abandon | 60 | 8 | 0 | No | No |
| 15814067 | INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITH | November 2017 | November 2018 | Abandon | 12 | 1 | 0 | No | No |
| 15814197 | INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITH | November 2017 | November 2018 | Abandon | 12 | 1 | 0 | No | No |
| 15566740 | POLYMERS FOR STABILISING PEROXIDE COMPOUNDS | October 2017 | September 2022 | Abandon | 59 | 4 | 1 | Yes | No |
| 15566230 | Whitening Systems for Hydrophobic Whitening Gels | October 2017 | August 2021 | Allow | 46 | 2 | 1 | No | No |
| 15711510 | COMPOSITION FOR REMOVING DENTAL PLAQUE AND TARTAR | September 2017 | January 2021 | Allow | 40 | 2 | 1 | Yes | No |
| 15708556 | Oral Care Compositions and Methods of Use | September 2017 | June 2021 | Allow | 45 | 3 | 1 | Yes | No |
| 15700432 | HAIR CARE COMPOSITIONS COMPRISING GLYCERIDE COPOLYMERS | September 2017 | December 2020 | Abandon | 39 | 2 | 1 | No | No |
| 15684226 | Oral Care Compositions | August 2017 | May 2022 | Allow | 57 | 4 | 1 | No | Yes |
| 15680241 | TAMPER RESISTANT DOSAGE FORMS | August 2017 | August 2019 | Abandon | 24 | 1 | 0 | No | No |
| 15670522 | HYLA3D HYALURONIC ACID ACTIVATING LIP COMPLEX | August 2017 | January 2020 | Allow | 29 | 2 | 1 | Yes | No |
| 15548468 | Oral Care Compositions and Methods of Use | August 2017 | March 2024 | Abandon | 60 | 6 | 1 | No | Yes |
| 15548272 | Oral Care Compositions and Methods of Use | August 2017 | September 2023 | Abandon | 60 | 8 | 1 | No | No |
| 15661705 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | July 2017 | November 2019 | Abandon | 28 | 2 | 0 | No | No |
| 15649861 | PROCESS FOR MAKING ORAL CARE COMPOSITIONS | July 2017 | January 2022 | Abandon | 55 | 7 | 1 | No | No |
| 15646102 | ORALLY DISINTEGRATING TABLET AND METHOD FOR PRODUCING SAME | July 2017 | November 2020 | Abandon | 40 | 4 | 1 | Yes | No |
| 15646617 | OPHTHALMIC DEVICES FOR SUSTAINED DELIVERY OF ACTIVE COMPOUNDS | July 2017 | November 2020 | Abandon | 40 | 2 | 1 | No | Yes |
| 15634579 | Organic Compounds | June 2017 | March 2019 | Abandon | 20 | 1 | 0 | No | No |
| 15539753 | METHOD FOR PRODUCING LIQUID COMPOSITION FOR ORAL CAVITY AND LIQUID COMPOSITION FOR ORAL CAVITY | June 2017 | November 2020 | Allow | 41 | 4 | 1 | Yes | No |
| 15539748 | Zinc Phosphate Complex for Oral Care | June 2017 | February 2024 | Allow | 60 | 8 | 0 | Yes | Yes |
| 15539725 | Zinc Phosphate Complex | June 2017 | February 2023 | Allow | 60 | 6 | 0 | Yes | Yes |
| 15539230 | Oral Care Compositions and Methods of Use | June 2017 | May 2024 | Allow | 60 | 8 | 0 | Yes | Yes |
| 15538330 | Zinc Phosphate Complex | June 2017 | February 2024 | Allow | 60 | 8 | 0 | No | Yes |
| 15537975 | Oral Care Composition | June 2017 | April 2020 | Abandon | 34 | 4 | 0 | No | No |
| 15625863 | ORAL FORMULATIONS OF DEFERASIROX | June 2017 | October 2020 | Abandon | 40 | 4 | 0 | Yes | Yes |
| 15533710 | Oral Care Composition | June 2017 | September 2022 | Abandon | 60 | 4 | 0 | No | Yes |
| 15533697 | Oral Care Composition | June 2017 | September 2022 | Abandon | 60 | 8 | 0 | No | No |
| 15613432 | Implantable Metallic Sheet for Bone Repair | June 2017 | November 2019 | Abandon | 30 | 2 | 1 | Yes | No |
| 15600732 | Method of preparing albumin nanoparticle carrier wrapping taxane drug | May 2017 | April 2019 | Allow | 23 | 3 | 0 | Yes | No |
| 15596875 | RAPID DISPERSE DOSAGE FORM | May 2017 | May 2018 | Abandon | 12 | 7 | 0 | No | No |
| 15521058 | Preparation of Zinc Citrate and of Zinc Citrate-Containing Oral Care Compositions | April 2017 | August 2021 | Allow | 52 | 6 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MILLIGAN, ADAM C.
With a 35.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MILLIGAN, ADAM C works in Art Unit 1612 and has examined 507 patent applications in our dataset. With an allowance rate of 20.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner MILLIGAN, ADAM C's allowance rate of 20.3% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MILLIGAN, ADAM C receive 3.33 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MILLIGAN, ADAM C is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +38.2% benefit to allowance rate for applications examined by MILLIGAN, ADAM C. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 5.9% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 9.3% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 14.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 45.1% of appeals filed. This is in the 12% percentile among all examiners. Of these withdrawals, 24.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 70.5% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.